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Pharmacogenetic Risk Scores for Perindopril Clinical and Cost
Effectiveness in Stable Coronary Artery Disease: When Are We Ready
to Implement?
Jasmine A. Luzum, PharmD, PhD, BCPS; David E. Lanfear, MD, MS, FAHA
I n this issue of the Journal of the American HeartAssociation, Oemrawsingh et al present a very interesting
and well-executed analysis of clinical and pharmacogenetic
risk scores for perindopril effectiveness in 8726 patients with
stable coronary artery disease.1 Their results demonstrate
that the clinical risk score can predict patient risk but not the
relative risk reduction of the therapy, which was homoge-
neous across clinical risk groups. In contrast, the pharmaco-
genetic risk scores could differentiate patients in terms of the
effectiveness of therapy; in the 26.5% of patients with a risk
score >2, perindopril was not associated with clinical benefit
(primary end point: cardiovascular mortality, nonfatal myocar-
dial infarction, or resuscitated cardiac arrest), while an
enhanced benefit was seen in the remaining 73.5%. The
authors then added to this by quantifying the clinical and cost
implications of various clinical and pharmacogenetic risk
score strategies. Genetically testing all patients and only
treating those with a pharmacogenetic risk score ≤2 was
equally clinically effective and more cost-effective compared
to standard care (ie, no genetic testing, all patients are
treated with perindopril).
By combining the pharmacogenetic risk score with a
published clinical risk score2 and analyzing the cost-
effectiveness of the combination, this study by Oemrawsingh
et al is an important extension of their initial publication of
the pharmacogenetic risk score in 2010.3 The current study
has several strengths: large sample size, randomized con-
trolled data, assessment of pharmacogenetic risk factors in
the context of clinical risk strata, inclusion of a cost-
effectiveness analysis, and the relative simplicity of the
pharmacogenetic score. However, like many excellent publi-
cations, this one prompts as many questions as it answers.
Are we ready to accept the likelihood that 1 in 4 stable
coronary artery disease patients are treated ineffectively (or
perhaps even harmfully?) with perindopril, wasting precious
resources and effort? Should we implement pharmacogenetic
tailored therapy now, and if not, when will we have sufficiently
convincing data to do so? While the United States Food and
Drug Administration (FDA) has incorporated genetics into the
prescribing information for >130 drugs4 (Table), and the
Clinical Pharmacogenetics Implementation Consortium has
published 33 guidelines on pharmacogenetic information
(Table),5 pharmacogenetics has not achieved significant use
in cardiology. There are several important barriers including
logistical and educational concerns,6 but equally important
and relevant to the work by Oemrawsingh et al are the cost
implications and unclear standards for levels of evidence
required to justify pharmacogenetic testing.
Regarding costs, the current work is very helpful. Oem-
rawsingh et al estimated the cost to genotype all 3 variants
used in their pharmacogenetic risk score to be only €15 euros
(approximately $17 USD), and currently, 2.5 million genetic
variants in an individual patient can be simultaneously tested
in a single sample for around $300 USD. For comparison, a
single comprehensive metabolic panel, which is often
repeated annually, costs around $600. Unlike many other
types of laboratory tests, the patient’s DNA is static, and thus
genetic testing only needs to be performed once to provide
lifetime results. Despite the declining costs of genetic testing
and examples of cost-effectiveness as reported by Oem-
rawsingh et al, the barrier that patients and providers most
often face is lack of reimbursement for pharmacogenetic
testing (not only in the United States but in Europe as well).7,8
Pharmacogenetic tests for most cardiovascular drugs are not
reimbursed, except for clopidogrel and warfarin. For example,
7 different third-party payers, including Medicare, have
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reimbursed for a clopidogrel pharmacogenetic test, with an
85% reimbursement rate.9 Although Oemrawsingh et al
demonstrated cost-effectiveness for their perindopril pharma-
cogenetic strategy, cost-effectiveness is often not enough to
gain reimbursement. According to case studies published in
2010, the strongest predictor of pharmacogenetic test
reimbursement is the strength of available evidence.7
In terms of level of evidence, the PERGENE study and idea
of pharmacogenetic-guided treatment for angiotensin-con-
verting enzyme (ACE) inhibitors in stable coronary artery
disease still needs some additional steps. We feel most
observers would agree that the pharmacogenetic risk score
presented by Oemrawsingh et al must be, at a minimum,
replicated in an independent data set before it can be taken
forward. However, this should be quite achievable, and should
be a high-priority research topic. We also do not know that the
same pharmacogenetic effect is at play for other ACE
inhibitors, though a class effect seems likely. Ideally a
validating study could answer both of these questions (ie,
testing a distinct patient cohort and a different ACE inhibitor).
Another issue is that the mechanisms of the genetic variants
used in the pharmacogenetic risk score are unknown (Figure);
the authors selected genetic variants based on linkage
disequilibrium.3 Moreover, linkage disequilibrium differs
depending on ancestry, and thus this pharmacogenetic risk
score may not be applicable to patients who are not of
Table. Cardiovascular Drugs With Pharmacogenetic Information Included in the US FDA Prescribing Information and CPIC guidelines.
Drug Source Summary of Pharmacogenetic Information
Carvedilol US FDA “Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness
during up-titration”
Clopidogrel US FDA “Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.” (Black
Box Warning)
Clopidogrel CPIC “The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy (eg, prasugrel, ticagrelor) for
CYP2C19 poor or intermediate metabolizers if there is no contraindication.”
Isosorbide and
hydralazine
US FDA “Hydralazine is metabolized by acetylation . . . About 50% of patients are fast acetylators and have lower exposure” “In
patients with heart failure, mean absolute bioavailability of a single oral dose of hydralazine 75 mg varies from 10% to
26%, with the higher percentages in slow acetylators.”
Metoprolol US FDA “Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor
metabolizers) and about 2% of most other populations.” “Poor metabolizers and extensive metabolizers who
concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing
metoprolol’s cardioselectivity.”
Prasugrel US FDA “There is no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of
prasugrel’s active metabolite or its inhibition of platelet aggregation.”
Propafenone US FDA “Simultaneous use with both a CYP3A4 and CYP2D6 inhibitor (or in patients with CYP2D6 deficiency) should be avoided.”
Propranolol US FDA “In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers (EMs) and poor metabolizers
(PMs) with respect to oral clearance or elimination half-life.”
Quinidine US FDA “Quinidine is not metabolized by cytochrome P450IID6, but therapeutic serum levels of quinidine inhibit the action of
cytochrome P450IID6, effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised
whenever quinidine is prescribed together with drugs metabolized by cytochrome P450IID6.”
Ticagrelor US FDA “In a genetic substudy cohort of PLATO, the rate of thrombotic CV events in the BRILINTA arm did not depend on
CYP2C19 loss of function status.”
Simvastatin CPIC “The FDA recommends against 80 mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 rs4149056,
there are modest increases in myopathy risk even at lower simvastatin doses (40 mg daily); if optimal efficacy is not
achieved with a lower dose, alternate agents should be considered.”
Warfarin US FDA “CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the initial dose of warfarin.” (A
table of expected warfarin maintenance doses based on CYP2C9 and VKORC1 genotypes is provided.)
Warfarin CPIC “The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on http://
www.warfarindosing.org.” (This recommendation is from 2011. CPIC guideline authors are aware of more recently
published warfarin pharmacogenetic studies and will incorporate them into an updated guideline.)
Data from http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics and with guidelines published by CPIC (www.PharmGKB.org). 2D6 indicates cytochrome
P450 family 2 subfamily D member 6; CPIC, Clinical Pharmacogenetics Implementation Consortium of the U.S. National Institutes of Health’s Pharmacogenomics Research Network;
CYP2B6, cytochrome P450 family 2 subfamily B member 6; CYP2C9, cytochrome P450 family 2 subfamily C member 9; CYP2C19, cytochrome P450 family 2 subfamily C member 19;
CYP2D6, cytochrome P450 family 2 subfamily D member 6; CYP3A4, cytochrome P450 family 3 subfamily A member 4; CYP3A5, cytochrome P450 family 3 subfamily A member 5;
P450IID6, cytochrome P450 family 2 subfamily D member 6; PLATO, trial of ticagrelor vs clopidogrel in patients with acute coronary syndromes; SLCO1B1, solute carrier organic anion
transporter family member 1B1; US FDA, United States Food and Drug Administration; VKORC1, vitamin K epoxide reductase complex subunit 1.
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European ancestry. Given this, and the well-recognized racial
variation in effectiveness of many cardiovascular medications,
additional validation studies of this pharmacogenetic test in
patients of non-European ancestry are necessary and would
be required prior to contemplating using it for clinical
purposes in other racial groups.
Assuming that the Oemrawsingh et al findings can be
replicated, should this strategy then be clinically imple-
mented? First consider the myriad of nongenetic patient
factors that we constantly use to guide cardiovascular drug
therapy without prospective trial data. For example, co-
treatment of omeprazole with clopidogrel is often avoided due
Figure. Agents acting on the renin–angiotensin system pathway ©PharmGKB. Reproduced with
permission from the Pharmacogenomics Knowledge Base (PharmGKB) and Stanford University (https://
www.pharmgkb.org/pathway/PA165110622#PGG).5 ACE indicates angiotensin-converting enzyme; AGT,
angiotensinogen; AGTR1, angiotensin II receptor type 1; AGTR2, angiotensin II receptor type 2; Ang,
angiotensin; ARB, angiotensin receptor blocker; ATP6AP2, ATPase H+ transporting accessory protein 2;
BDKRB1, bradykinin receptor B1; BDKRB2, bradykinin receptor B2; CMA1, chymase 1; CTSG, cathepsin G;
CYP11B2, cytochrome P450 family 11 subfamily B member 2; KNG, kininogen; MAPK1, mitogen-activated
protein kinase 1; MAPK3, mitogen-activated protein kinase 3; MAS1, MAS1 proto-oncogene; MME,
membrane metallo-endopeptidase; NOS3, nitric oxide synthase 3; NR3C2, nuclear receptor subfamily 3
group C member 2; PK, pharmacokinetic; REN, renin; TGFB1, transforming growth factor b1.
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to a drug–drug interaction without prospective trial data.
However, the pharmacogenetic effects on clopidogrel are just
as strong as the drug–drug interaction with omeprazole.10
Warfarin dose is empirically decreased in patients starting
amiodarone due to a drug–drug interaction without prospec-
tive trial data.11 However, the pharmacogenetic effects on
warfarin dose are stronger than the drug–drug interaction
with amiodarone.12 Patients are advised to avoid grapefruit
juice while taking simvastatin due to a drug–food interaction
without prospective trial data.13 However, the pharmacoge-
netic effects on simvastatin blood concentrations are just as
large as the effects of the drug–food interaction with
grapefruit juice.14 Similar to nongenetic factors used to guide
drug therapy, the decision to use pharmacogenetic testing
should consider the total risks and benefits, including, for
example, the severity of potential side effects averted, or the
difference in efficacy, and even the cost/potential savings.
An argument often used against comparing genetic to
nongenetic factors to guide drug therapy is that nongenetic
factors are usually readily available, but genetic test results are
not. However, keep in mind that we also delay drug therapy
based on nongenetic factors. For example, the initiation of ACE
inhibitor therapy is delayed until the return of laboratory results
ruling out renal insufficiency. Moreover, the lack of readily
available genetic test results may no longer be an issue since
many institutions and laboratories (http://www.ncbi.nlm.nih.
gov/gtr/) now offer pharmacogenetic testing. More impor-
tantly, with the continually decreasing cost and increasing scale
of genetic testing, it is anticipated that genetics will ultimately
become a routine part of the electronic medical record for all
patients. Thus, there are many current situations where genetic
information could impact clinical decisions in terms of “best
available evidence,” even if it does not meet the commonly held
evidence-based medicine standards of having multiple clinical
trials on a single intervention.
A second consideration is whether we are holding pharma-
cogenetics to an unequal standard. In a 2015 Scientific
Statement by the American Heart Association,15 the authors
recommended against pharmacogenetic testing for clopidogrel
because “. . . no clinical trials assessing the utility of a CYP2C19
genotype test to guide and tailor therapy in a way that leads to
improved patient outcomes have been published . . .” However,
in the same 2015 Scientific Statement, the authors endorse
genetic testing for long QT syndrome, stating it “can potentially
help guide patient management,” and they provide recommen-
dations for potential interventionswithout prospective trial data.
Moreover, in cancer treatment guidelines, pharmacogenetic
recommendations for thiopurine drugs are widely accepted but
not informed by a randomized controlled trial.16,17
The standard of evidence required for the clinical imple-
mentation of pharmacogenetic testing is widely debated.18
The “gold standard” of evidence for pharmacogenetic appli-
cations, as stated in a 2012 Special Report on Cardiovascular
Pharmacogenomics in the Journal of the American Heart
Association is “a prospective trial with treatment determined
by genotype and with a clinical end point as the primary
outcome . . .”19 The study by Oemrawsingh et al falls short of
this because it is a retrospective analysis of a prospective
clinical trial. However, the authors of the 2012 Special Report
do state “. . . it also recognized that it would be very difficult to
sustain and fund a large number of such trials.” This is an
understatement; it would be nearly impossible to perform a
genetically guided randomized trial for every possible drug
and indication, particularly drugs that are already FDA
approved. Indeed, a single prospective trial takes several
years to complete and costs tens of millions of dollars (or
more). The authors of the 2012 Special Report go on to say
“. . . in some cases the weight of evidence from observational
studies may be so compelling as to render prospective trials
unnecessary.”19 We agree with this assertion and posit that
what is needed is more clarity regarding what this level of
evidence should look like so that widely acceptable and
achievable standards can exist. We would propose that
retrospective analyses of multiple prospective clinical trials
validating a specified pharmacogenetic approach should be
adequate evidence. As a further step, if there is evidence from
1 clinical trial (as in the case of the current study), validation
in an independent, adequately sized, and well-phenotyped
observational cohort (or vice versa) is likely enough to justify
clinical pharmacogenetic implementation. This is of course a
debatable point, but with a strong preponderance of evidence,
and the best interest of all patients in mind, we feel it may be
most satisfactory. The alternative of ignoring congruent data
from multiple large studies and simply continuing a standard
of care that is wasteful (and even potentially harmful) in an
easily identifiable subgroup of patients seems unappealing.
In conclusion, the study by Oemrawsingh et al is an
important contribution despite the fact that the pharmacoge-
netic association is not new. It spotlights a practical path
forward to precision medicine for ACE inhibitors in stable
coronary artery disease, and it quantifies the motivation for
doing so in terms of clinical and cost-effectiveness. The major
limitation of the study is the lack of a sufficient replication
data set. If validation testing can be achieved, then clinical
care can be fundamentally altered. While there are other
scientific questions remaining regarding the mechanisms of
the genetic variants, the alternative therapy in patients with a
pharmacogenetic risk score >2, and application in non-
European ancestry patients, these can be addressed in
additional future studies. More important is to hear this as a
wake-up call so that the clinical and scientific communities
can reach a better consensus regarding when and how to put
findings like these into action clinically. Improved care for our
patients is waiting.
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